open access
Assessing the merits of existing pancreatic cancer biomarkers
Affiliations- Department of Medical and Molecular Biology, Medical University of Silesia, Zabrze, Poland
open access
Abstract
Pancreatic ductal adenocarcinoma (PDAC) suffers from a very poor prognosis because early stages of the disease are asymptomatic and thus diagnosis is delayed until late. Discovering a suitable PDAC biomarker could thereby improve PDAC treatment by having an early diagnosis. The carbohydrate antigen, CA 19-9, currently used for diagnostics, may help in assessing the disease stage, however it is unsuitable for screening purposes. PDAC specific nucleotides can be detected in plasma but not at the early stages of the cancer. Furthermore, measuring circulating tumour cells (CTCs) in patient blood entails high costs and is only useful for advanced stage disease. Other potential PDAC marker candidates are Laminin g2A, Cyclophilin B and blood circulating adipokines, which seem to hold particular promise. At present, making early PDAC diagnosis is limited. The potential markers described herein might in the future be introduced into clinical practice however further studies are still required. Using combinations of several biomarkers also merit consideration, which may increase the overall sensitivity and specificity of PDAC detection.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) suffers from a very poor prognosis because early stages of the disease are asymptomatic and thus diagnosis is delayed until late. Discovering a suitable PDAC biomarker could thereby improve PDAC treatment by having an early diagnosis. The carbohydrate antigen, CA 19-9, currently used for diagnostics, may help in assessing the disease stage, however it is unsuitable for screening purposes. PDAC specific nucleotides can be detected in plasma but not at the early stages of the cancer. Furthermore, measuring circulating tumour cells (CTCs) in patient blood entails high costs and is only useful for advanced stage disease. Other potential PDAC marker candidates are Laminin g2A, Cyclophilin B and blood circulating adipokines, which seem to hold particular promise. At present, making early PDAC diagnosis is limited. The potential markers described herein might in the future be introduced into clinical practice however further studies are still required. Using combinations of several biomarkers also merit consideration, which may increase the overall sensitivity and specificity of PDAC detection.
Keywords
PDAC, biomarkers, miRNA, adipokine, adiponectin, laminin, cyclophilin
About this articleTitle
Assessing the merits of existing pancreatic cancer biomarkers
Journal
Nowotwory. Journal of Oncology
Issue
Article type
Review paper
Pages
201-205
Published online
2017-12-12
Page views
557
Article views/downloads
726
DOI
Bibliographic record
Nowotwory. Journal of Oncology 2017;67(3):201-205.
Keywords
PDAC
biomarkers
miRNA
adipokine
adiponectin
laminin
cyclophilin
Authors
Paweł Kiczmer
Alicja Prawdzic Seńkowska
Błażej Szydło
Elżbieta Świętochowska
Zofia Ostrowska